Table 1.
Patients’ characteristics at baseline.
| T/R | R/T | p-Value | T | R | p-Value | |
|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |||
| Total | 146 (16.8) | 116 (13.3) | 325 (37.5) | 279 (32.2) | ||
| Median age (years) | 69 (-) | 66 (-) | 71 (-) | 65 (-) | ||
| Patients ≥ 70yrs | 0.1306 | <0.00001 | ||||
| yes | 67 (45.8) | 42 (36.2) | 178 (54.7) | 97 (34.7) | ||
| no | 79 (54.1) | 74 (63.7) | 147 (45.2) | 182 (65.2) | ||
| Gender | 0.6981 | 0.4115 | ||||
| Female | 51 (34.9) | 44 (37.9) | 149 (45.8) | 118 (42.2) | ||
| Male | 95 (65.0) | 72 (62.0) | 176 (54.1) | 161 (57.7) | ||
| RAS status | 0.5986 | 0.1807 | ||||
| Wild type | 49 (33.5) | 42 (36.2) | 122 (37.5) | 122 (43.7) | ||
| Mutant type | 90 (61.6) | 67 (57.7) | 195 (60.0) | 154 (55.1) | ||
| Tumor location | 0.2926 | 0.6611 | ||||
| Right side | 52 (35.6) | 34 (29.3) | 100 (30.7) | 91 (32.6) | ||
| Left side | 94 (64.3) | 82 (70.6) | 225 (69.2) | 188 (67.3) | ||
| MSI | 0.4594 | 0.675 | ||||
| yes | 3 (2.0) | 4 (3.4) | 3 (0.9) | 3 (1.0) | ||
| no | 89 (60.9) | 64 (55.1) | 177 (54.4) | 105 (37.6) | ||
| ECOG PS | 0.2113 | 0.3228 | ||||
| 0–1 | 128 (87.6) | 108 (93.1) | 250 (76.9) | 224 (80.2) | ||
| 2 | 18 (12.3) | 8 (6.8) | 75 (23.0) | 55 (19.7) | ||
| Prior adjuvant therapy | 0.232 | 0.0094 | ||||
| yes | 46 (31.5) | 43 (37.0) | 90 (27.6) | 52 (18.6) | ||
| no | 100 (68.4) | 66 (56.8) | 235 (72.3) | 227 (81.3) | ||
| Metastatic disease sites | 0.4418 | 0.4508 | ||||
| Liver only | 23 (15.7) | 14 (12.0) | 38 (11.6) | 31 (11.1) | ||
| Liver + other | 80 (54.7) | 51 (43.9) | 133 (40.9) | 156 (55.9) | ||
| Others | 43 (29.4) | 51 (43.9) | 154 (47.3) | 92 (32.9) | ||
| CT 1°line regimen | 0.4008 | 0.6262 | ||||
| Doublet chemotherapy | 112 (76.7) | 94 (81.0) | 265 (81.5) | 140 (50.1) | ||
| Triplet chemotherapy | 16 (10.9) | 9 (7.7) | 33 (10.1) | 14 (5.0) | ||
| CT 2°line regimen | 1 | 0.3015 | ||||
| Doublet chemotherapy | 119 (81.5) | 94 (81.0) | 258 (79.3) | 119 (42.6) | ||
| Triplet chemotherapy | 2 (1.3) | 2 (1.7) | 5 (1.5) | 5 (1.7) | ||
| CT 3°line regimen | 0.6221 | 0.3334 | ||||
| Fluoropyrimidine alone | 3 (2.0) | 2 (1.7) | 4 (1.2) | 8 (2.8) | ||
| Doublet chemotherapy | 9 (6.1) | 15 (12.9) | 19 (5.8) | 18 (6.4) | ||
| Biological agents 1°line | 0.3873 | 0.378 | ||||
| Anti-EGFR use | 43 (29.4) | 30 (25.8) | 86 (26.4) | 52 (18.6) | ||
| Anti-VEGF use | 72 (49.3) | 65 (56.0) | 176 (54.1) | 87 (31.1) | ||
| Biological agents 2°line | 1 | 0.5379 | ||||
| Anti-EGFR use | 9 (6.1) | 7 (6.0) | 17 (5.2) | 11 (3.9) | ||
| Anti-VEGF use | 97 (66.4) | 81 (69.8) | 198 (60.9) | 100 (35.8) | ||
| Biological agents 3°line | 0.7089 | 0.747 | ||||
| Anti-EGFR use | 10 (6.8) | 10 (8.6) | 13 (4.0) | 12 (4.3) | ||
| Anti-VEGF use | 4 (2.7) | 6 (5.1) | 9 (2.7) | 6 (2.1) |
Abbreviations: T, trifluridine/tipiracil; R, regorafenib; CT, chemotherapy; MSI, micro-satellites’ instability; PS, performance status.